Compare Veritone Inc (VERI) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Veritone Inc vs Zoetis Inc — how do they compare? Veritone Inc trades at $0.54 (market cap $59.46M), while Zoetis Inc trades at $74.56 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 507.9× Veritone Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Veritone Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Veritone Inc for 12 Days and Zoetis Inc for 70 Days on average.
| VERI | ZTS | |
|---|---|---|
Market Cap | $59.46M | $30.20B |
Volume | 15,523,164 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $8.39 | $147.53 |
52-Week Low | $0.59 | $69.09 |
Typical Hold Time | 12 Days | 70 Days |
Enterprise Value | $94.86M | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Veritone (VERI) trades at $0.58, down 16% today, reflecting ongoing investor concerns despite some positive business developments. The stock shows bearish technical signals with moving averages indicating strong selling pressure, while fundamentals reveal significant challenges with a -117.5% net income margin and consistent quarterly losses. Recent news includes a $15 million equity offering and partnerships with ATP Media and ZeroEyes, though these are offset by ongoing securities litigation investigations.
The outlook remains challenging with persistent losses and negative cash flow from operations, though analyst consensus suggests substantial upside potential with a $3.75 price target. Key risks include the company's inability to achieve profitability, competitive pressures in AI solutions, and legal uncertainties. The stock presents high-risk speculation with potential for recovery if cost reductions and new partnerships drive meaningful revenue growth.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
